Anette Løken Eilertsen

Author network for Anette Løken Eilertsen by COREMINE medical

Publications 2014

Jacobsen AF, Kristiansen A, Bjørge L, Henriksen T, Eilertsen AL, Sandset PM (2014)
[Anticoagulation for venous thrombosis in pregnancy]
Tidsskr Nor Laegeforen, 134 (9), 926
PubMed 24828717

Publications 2012

Dahm AE, Eilertsen AL, Goeman J, Olstad OK, Ovstebø R, Kierulf P, Mowinckel MC, Skretting G, Sandset PM (2012)
A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women
Thromb Res, 130 (1), 45-51
PubMed 22217510

Publications 2010

Opstad TB, Eilertsen AL, Høibraaten E, Skretting G, Sandset PM (2010)
Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy
Blood Coagul Fibrinolysis, 21 (6), 516-21
PubMed 20453636

Publications 2009

Sandset PM, Høibraaten E, Eilertsen AL, Dahm A (2009)
Mechanisms of thrombosis related to hormone therapy
Thromb Res, 123 Suppl 2, S70-3
PubMed 19217481

Publications 2008

Eilertsen AL, Karssemeijer N, Skaane P, Qvigstad E, Sandset PM (2008)
Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method
BJOG, 115 (6), 773-9
PubMed 18355366

Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM (2008)
Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers
J Thromb Haemost, 6 (6), 928-34
PubMed 18394014

Publications 2007

Andresen MS, Eilertsen AL, Abildgaard U, Sandset PM (2007)
Hormone therapy and raloxifene reduce the coagulation inhibitor potential
Blood Coagul Fibrinolysis, 18 (5), 455-60
PubMed 17581320

Eilertsen AL, Liestøl S, Mowinckel MC, Hemker HC, Sandset PM (2007)
Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system
Thromb Haemost, 97 (6), 938-43
PubMed 17549295

Publications 2006

Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM (2006)
Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation
Maturitas, 55 (3), 278-87
PubMed 16713143

Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM (2006)
Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis
Thromb Res, 120 (3), 371-9
PubMed 17156824

Negaard HF, Eilertsen AL, Dahm A, Iversen PO, Østenstad B, Sandset PM (2006)
Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?
J Clin Oncol, 24 (17), 2683-4; author reply 2684
PubMed 16763285

Publications 2005

Eilertsen AL, Høibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM (2005)
The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis
Maturitas, 52 (2), 111-8
PubMed 16186073